The “Cherry” Release of O-RAN Open Software Moves the O-RAN Ecosystem Closer to Deployment in Mobile Networks Around the Globe
In December 2020, the O-RAN Software Community (OSC), working with the Linux Foundation, published its 3rd open software release within 18 months, dubbed “Cherry”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005829/en/
O-RAN Logical Architecture (Graphic: Business Wire)
Cherry moves the O-RAN ecosystem closer to commercial deployments in mobile networks around the globe. On top of new functions aligned with the latest O-RAN specifications, such as the E2, A1 and O1 interfaces, this release also features significant advancements in the end-to-end integration of O-RAN Architecture components to meet the needs of early adopters. In addition, new software projects in the area of Service Management and Orchestration (SMO) have been initiated to drive the development of auto-configuration and management of O-RAN elements.
The main use cases delivered in Cherry include:
- Policy based Traffic Steering using the A1 and E2 interfaces
- Automated Monitoring and Health check of selected components using the O1 interface
- Configuration, Fault and Performance Management Services aligned with OAM models and specifications newly approved by O-RAN
- Life Cycle Management Framework of rApps and xApps using SMO
- O-DU Low and High pairwise testing in O-RAN Software Community lab
- Simulators for testing and integration, such as E2, A1, Open Test Framework, and more
“It is gratifying to see the continued momentum of the OSC’s open-source O-RAN implementation,” said Jack Murray, co-chair of the OSC Technical Operating Committee (TOC) and Assistant Vice President of AT&T. “AT&T is proud to have continued its contributions to enable RAN AI/ML through the Near-Real Time RIC implementation, and to provide a platform for software testing and integration.”
“We are glad to see Cherry has made big progress by building on the base of Bronze,” said Chih-Lin I, the Co-Chair of O-RAN Technical Steering Committee. “It not only realizes more 3GPP-defined models, but also brings O-RAN defined interfaces including E2 and A1 closer to commercialization. More ML and AI technologies are implemented in the RIC, RICAPP and NRTRIC projects to push the traffic steering e2e use case forward, which makes it a more intelligent RAN. The newly created SMO project is also worth special mention for the quick momentum that it has gained in contributing to O-RAN automation and management within just 3 months.”
“Nokia continues to be very active in O-RAN and a major contributor to the O-RAN specifications,” said Pasi Toivanen, Head of Edge Cloud Platforms at Nokia. “With the Cherry Release, Nokia is contributing to the Near-Real-Time RIC and the E2 interface to advance RAN programmability, network openness, and the introduction of AI/ML intelligence to the network. The contributions also deliver increased robustness, more xApp framework capabilities and enhanced manageability of RIC platform and xApps.”
“Radisys continues to contribute actively to O-RAN standardization and open source development. In the Cherry release, Radisys enhanced O-DU L2 implementation to support UE attach, and integrated with PHY (O-DU Low) through the FAPI interface to enable end-to-end testing," said Ganesh Shenbagaraman, Head of Integrated Products and Ecosystems at Radisys.
“highstreet technologies substantially contributes to O1/OAM within both O-RAN and OSC,” said Alfons Mittermaier, Managing Director of highstreet technologies. “We expect the disaggregated O-RAN architecture to become a door opener for small and medium sized enterprises and will deploy the Cherry release in a 5G reference network in Berlin.”
“HCL has contributed to the O-RAN Software Community across different Work Groups starting with the Cherry Release,” said Ramesh Sriraman, the Head of Telecom Center of Excellence at HCL. “We Improved Near-Real-Time RIC platform CI/CD deployment, automation, performance & scale; introduced AI/ML intelligence to RAN network via xApps; and contributed the initial implementation of the O-RAN O1 interface in the O-DU. It is a great honor for HCL to develop together with the OSC team.”
The O-RAN Software Community continues to be open to any participants that want to get involved in the creation of software for future RAN – for more details please visit https://www.o-ran.org/software.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 240 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org.
O-RAN ALLIANCE PR Contact
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis26.1.2021 14:00:00 CET | Press release
Mundipharma and Cidara Therapeutics today announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).4 The EMA considers ODD status for medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than five per 10,000 people in the EU.5 It is estimated that IC occurs in around 0.84 per 10,000 people in the EU,6 and mostly affects hospitalised, immunocompromised or critically ill patients.2 IC continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, mortality rates are as high as 40%.3 IC is characterised as a severe, life-threatening systemic Candida infection of the bloods
Software Industry: Nexway™ Reinforces the Customer Experience Capabilities of its Monetize Personalized Growth Platform26.1.2021 14:00:00 CET | Press release
Nexway, a leading software and service company for e-commerce and payments, is very excited to launch the latest features on its personalized growth platform Nexway Monetize, moving forward in its mission to expand the online footprint and sales potential of software vendors, games publishers and service providers across 140 countries around the world. In today’s uncertain business environment, the e-commerce and payment leader is looking to leverage its best technologies to offer a seamless purchase experience, helping its clients to remain flexible in their strategic approach to e-commerce. Nexway‘s teams are driving versatility, flexibility, and frictionless features to conquer new markets and expand into vertical sectors linked to customer monetization, subscriptions, and B2B sales management. Nexway also intends to continue growing thanks to its agility, expertise, and high level of the customer purchase experience. "Customer experience is a constantly moving target, changing to m
Velodyne Lidar Signs Multi-Year Sales Agreement with Emesent26.1.2021 13:00:00 CET | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year sales agreement to provide Puck LITE™ sensors to Emesent, a world-leader in drone autonomy, lidar mapping and data analytics. Emesent is using Velodyne’s lidar sensors to power its award-winning Hovermap mobile scanning system for mapping hazardous and GPS-denied environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005229/en/ Emesent’s Hovermap, equipped with a Velodyne Puck LITE™ sensor, has a colorization feature for its 3D point clouds that brings additional context for visualization and analysis. (Photo: Emesent) Hovermap, which can be hand-held or mounted to a drone, uses Puck LITE lidar as its primary perception and mapping sensor. Equally capable above ground or underground, indoors or out, Hovermap combines advanced collision avoidance and autonomous flight technologies to map challenging, inaccessible areas. Hovermap has a coloriza
Allurion Technologies Launches Virtual Care Suite to Transform the Consumer and Provider Experience26.1.2021 13:00:00 CET | Press release
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fallurion.com%2F&esheet=52366910&newsitemid=20210126005074&lan=en-US&anchor=Allurion%26%23174%3B+Technologies&index=1&md5=a32a2cae6846c1f555e8ab3892c63eae Allurion® Technologies, a pioneering leader in the development of innovative, scalable and trusted weight loss experiences, today announced a major milestone for its AllurionTM Weight Loss Program with the launch of its new digital health offering featuring the Allurion TM Health Tracker smartwatch, Allurion® Connected Scale, Allurion® mobile app, and the Allurion TM Clinic Dashboard, the first in a series of new provider services that make up the Allurion TM Virtual Care Suite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210126005074/en/ The Allurion Connected Scale and Health Tracker measure all aspects of body composition including weight, body fat, muscle mass, as well as activity data such as steps, ex
Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index26.1.2021 12:35:00 CET | Press release
Takeda Pharmaceutical Company Limited(TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index. “This honor underscores Takeda’s commitment to prioritizing patient needs by ensuring access to our life-transforming treatments,” said Christophe Weber, Takeda president and chief executive officer. “As a purpose-driven company that puts the patient at the center of everything we do, we are committed to not just inventing medicines but making sure patients can access transformative therapies.” The AtM Index is a rigorous, biennial research project combining data-collection, verification, scoring and analysis
IFF Announces Preliminary Fourth Quarter & Full Year 2020 Financial Results26.1.2021 12:35:00 CET | Press release
IFF (NYSE:IFF), a leading innovator of taste, scent, and nutrition & ingredients, today announced preliminary, unaudited financial results for the quarter ended December 31, 2020. “In collaboration with DuPont’s financial announcement today, and in connection with the Exchange Offer related to our combination with DuPont Nutrition & Biosciences, we are providing preliminary financial results for the fourth quarter and full year 2020,” said IFF Chairman and CEO Andreas Fibig. “We expect to finish 2020 with results coming in ahead of our expectations despite continued challenges and complexity of the pandemic. This performance is a direct testament to the diversity of our portfolio, the essential nature of our products, and the resiliency of our global teams to continuously deliver for our customers.” Mr. Fibig continued, “With the completion of our merger with DuPont N&B now just days away, we continue to see multiple paths to strong value creation for all our stakeholders. Upon closing
Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France26.1.2021 12:00:00 CET | Press release
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply Good Manufacturing Processes (GMP) certified medical cannabis products for experimentation in France. Tilray will supply GMP-produced medical cannabis products to serve patients in need for the duration of the French experiment (18-24 months), due to begin in the first quarter of 2021. Tilray products will be administered to qualifying patients in the French experiment, for whom existing treatments do not provide sufficient relief from their symptoms, and for therapeutic indications including: Neuropathic pain that is refractory to therapies currently available (drug or non-drug treatments); Certain forms of epilepsy that are drug-resistant; In certain persistent symptoms in oncology, related to cancer or anti-cancer treatment; In palliative care s